Search

Your search keyword '"Garzón Ibáñez, Mónica"' showing total 7 results
Start Over Author "Garzón Ibáñez, Mónica"
7 results on '"Garzón Ibáñez, Mónica"'

2. Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial

Author

Molina-Vila, Miguel-Angel, Stahel, Rolf A., Dafni, Urania, Jordana-Ariza, Núria, Balada-Bel, Ariadna, Garzón-Ibáñez, Mónica, García-Peláez, Beatriz, Mayo-de-las-Casas, Clara, Felip, Enriqueta, Curioni Fontecedro, Alessandra, Gautschi, Oliver, Peters, Solange, Massutí, Bartomeu, Palmero, Ramon, Ponce Aix, Santiago, Carcereny, Enric, Früh, Martin, Pless, Miklos, Popat, Sanjay, Cuffe, Sinead, Bidoli, Paolo, Kammler, Roswitha, Roschitzki-Voser, Heidi, Tsourti, Zoi, Karachaliou, Niki, and Rosell, Rafael

Published
2020
Full Text
View/download PDF

3. Annotating the next generation sequencing report

Author

Molina-Vila, Miguel A., primary, Mayo-de-las-Casas, Clara, additional, Garzón-Ibáñez, Mónica, additional, Jordana-Ariza, Núria, additional, García-Peláez, Beatriz, additional, Balada-Bel, Ariadna, additional, and Rosell, Rafael, additional

Published
2020
Full Text
View/download PDF

4. Detection of somatic mutations in peritoneal lavages and plasma of endometrial cancer patients: A proof‐of‐concept study

Author

Mayo‐de‐las‐Casas, Clara, primary, Velasco, Ana, additional, Sanchez, Douglas, additional, Martínez‐Bueno, Alejandro, additional, Garzón‐Ibáñez, Mónica, additional, Gatius, Sònia, additional, Ruiz‐Miró, Maria, additional, Gonzalez‐Tallada, Xavier, additional, Llordella, Ivana, additional, Tresserra, Francesc, additional, Rodríguez, Sonia, additional, Aldeguer, Erika, additional, Roman‐Canal, Berta, additional, Bertran‐Alamillo, Jordi, additional, García‐Peláez, Beatriz, additional, Rosell, Rafael, additional, Molina‐Vila, Miguel A., additional, and Matias‐Guiu, Xavier, additional

Published
2020
Full Text
View/download PDF

5. An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer

Author

Mayo-de-las-Casas, Clara, primary, Garzón Ibáñez, Mónica, additional, Jordana-Ariza, Núria, additional, García-Peláez, Beatriz, additional, Balada-Bel, Ariadna, additional, Villatoro, Sergio, additional, Malapelle, Umberto, additional, Karachaliou, Niki, additional, Troncone, Giancarlo, additional, Rosell, Rafael, additional, and Molina-Vila, Miguel Angel, additional

Published
2017
Full Text
View/download PDF

6. Evolution and Clinical Impact of EGFRMutations in Circulating Free DNA in the BELIEF Trial

Author

Molina-Vila, Miguel-Angel, Stahel, Rolf A., Dafni, Urania, Jordana-Ariza, Núria, Balada-Bel, Ariadna, Garzón-Ibáñez, Mónica, García-Peláez, Beatriz, Mayo-de-las-Casas, Clara, Felip, Enriqueta, Curioni Fontecedro, Alessandra, Gautschi, Oliver, Peters, Solange, Massutí, Bartomeu, Palmero, Ramon, Ponce Aix, Santiago, Carcereny, Enric, Früh, Martin, Pless, Miklos, Popat, Sanjay, Cuffe, Sinead, Bidoli, Paolo, Kammler, Roswitha, Roschitzki-Voser, Heidi, Tsourti, Zoi, Karachaliou, Niki, and Rosell, Rafael

Abstract

Longitudinal evaluation of mutations in blood samples was a prespecified secondary objective in the BELIEF trial of erlotinib and bevacizumab in advanced EGFR-positive NSCLC. Here, we report the testing results and explore the correlation of EGFRstatus in blood with clinical outcomes.

Published
2020
Full Text
View/download PDF

7. An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer.

Author

Mayo-de-las-Casas, Clara, Garzón Ibáñez, Mónica, Jordana-Ariza, Núria, García-Peláez, Beatriz, Balada-Bel, Ariadna, Villatoro, Sergio, Malapelle, Umberto, Karachaliou, Niki, Troncone, Giancarlo, Rosell, Rafael, and Molina-Vila, Miguel Angel

Abstract

Introduction: Collection of tumor samples is not always feasible in non-small cell lung cancer (NSCLC) patients, and circulating free DNA (cfDNA) extracted from blood represents a viable alternative. Different sensitive platforms have been developed for genetic cfDNA testing, some of which are already in clinical use. However, several difficulties remain, particularly the lack of standardization of these methodologies. Areas covered: Here, the authors present a review of the literature to update the applicability of cfDNA for diagnosis and monitoring of NSCLC patients. Expert commentary: Detection of somatic alterations in cfDNA is already in use in clinical practice and provides valuable information for patient management. Monitoring baseline alterations and emergence of resistance mutations is one of the most important clinical applications and can be used to non-invasively track disease evolution. Today, different technologies are available for cfDNA analysis, including whole-genome or exome sequencing and targeted methods that focus on a selection of genes of interest in a specific disease. In the case of Next Generation Sequencing (NGS) approaches, in depth coverage of candidate mutation loci can be achieved by selecting a limited number of targeted genes. [ABSTRACT FROM PUBLISHER]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results